Notable Labs (NTBL) News Today → [URGENT] DO NOT Touch These AI Stocks! (From Weiss Ratings) (Ad) Buy NTBL with Qtrade Free NTBL Stock Alerts $1.02 -0.02 (-1.92%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 5:30 AM | americanbankingnews.comNotable Labs (NASDAQ:NTBL) Price Target Cut to $5.00May 16 at 1:07 PM | investorplace.comNTBL Stock Earnings: Notable Labs Misses EPS for Q1 2024May 16 at 10:04 AM | markets.businessinsider.comBuy Rating Affirmed for Notable Labs Amid Promising Drug Program and Robust PPMP PlatformMay 15, 2024 | sfgate.comNotable Labs: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comNotable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024May 9, 2024 | msn.comTivic Health, RAPT Therapeutics, Notable Labs among healthcare moversApril 30, 2024 | seekingalpha.comNTBL Notable Labs, Ltd.April 16, 2024 | msn.comCisco To Rally Around 24%? Here Are 10 Top Analyst Forecasts For MondayApril 15, 2024 | markets.businessinsider.comBuy Rating for Notable Labs: Financial Stability and Strategic Advances in AML Clinical TrialsApril 12, 2024 | investorplace.comNTBL Stock Earnings: Notable Labs Misses EPS for Q4 2023April 12, 2024 | globenewswire.comNotable Labs Reports 2023 Financial Results and Provides a Business UpdateApril 10, 2024 | investing.comNotable Labs advances cancer treatment with cryopreserved samplesApril 9, 2024 | globenewswire.comNotable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024April 8, 2024 | globenewswire.comNotable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the PlatformMarch 5, 2024 | globenewswire.comNotable Labs to Present Two Posters at AACR 2024 on PPMP PlatformMarch 5, 2024 | globenewswire.comNotable Labs to Present Two Posters at AACR 2024 on PPMP PlatformFebruary 22, 2024 | finance.yahoo.comNotable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided EnrollmentFebruary 22, 2024 | globenewswire.comNotable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided EnrollmentDecember 21, 2023 | markets.businessinsider.comMaintained Buy Rating on Notable Labs with Adjusted Price Target Amid Drug Setback and PPMP Platform PotentialDecember 18, 2023 | finance.yahoo.comNotable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial OutcomeDecember 18, 2023 | finance.yahoo.comNotable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial OutcomeDecember 14, 2023 | investing.comNotable Labs Ltd (NTBL)December 13, 2023 | finance.yahoo.comNotable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic SyndromesDecember 11, 2023 | finance.yahoo.comNotable Labs Funds Myelodysplastic Syndromes Foundation with $60,000 GrantDecember 4, 2023 | finance.yahoo.comNotable Labs to Participate in JMP Securities Hematology and Oncology SummitNovember 29, 2023 | morningstar.comNotable Labs Ltd NTBLNovember 21, 2023 | markets.businessinsider.comKeay Nakae’s Buy Rating on Notable Labs: Predictive Precision Medicine Platform and Financial Stability as Key FactorsNovember 16, 2023 | washingtonpost.comNotable Labs: Q3 Earnings SnapshotNovember 16, 2023 | finance.yahoo.comNotable Labs Announces Filing of Form 10-Q for Third Quarter 2023October 17, 2023 | marketbeat.comTrading was temporarily halted for "NTBL" at 01:10 PM with a stated reason of "LULD pause."October 17, 2023 | marketbeat.comTrading was temporarily halted for "NTBL" at 01:10 PM with a stated reason of "LULD pause." Trading set to resume at 01:10 PM. October 17, 2023 | marketbeat.comTrading was temporarily halted for "NTBL" at 10:10 AM with a stated reason of "LULD pause."October 17, 2023 | marketbeat.comTrading was temporarily halted for "NTBL" at 10:10 AM with a stated reason of "LULD pause." Get Notable Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for NTBL and its competitors with MarketBeat's FREE daily newsletter. Email Address Most important medical advance in 100 years (Ad)This is going to dramatically alter medicine forever. Keep in mind, creating a new effective drug in the past took up to 10 years and could cost up to $12 billion. But now, with artificial intelligence, it could take months and cost a fraction of that amount. Watch my new presentation detailing the opportunity NTBL Media Mentions By Week NTBL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTBL News Sentiment▼0.120.42▲Average Medical News Sentiment NTBL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTBL Articles This Week▼61▲NTBL Articles Average Week Get Notable Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for NTBL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Onconetix News Sonoma Pharmaceuticals News 60 Degrees Pharmaceuticals News Salarius Pharmaceuticals News Agile Therapeutics News Altamira Therapeutics News Avenue Therapeutics News Dermata Therapeutics News Virpax Pharmaceuticals News Clearmind Medicine News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTBL) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressMost important medical advance in 100 yearsThe Oxford ClubUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingNext President (Not Trump. Not Biden.)The Freeport Society41 banks launch ‘crypto dollar’Stansberry ResearchWhat’s Really Next for America…Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Notable Labs, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
